文献速递药物相互作用药物不良反应与药物警戒

注意缺陷多动障碍的个体化给药方案:哌甲酯与右哌甲酯制剂的使用指导

Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
PubMed 文献 · Pharmacotherapy · 2018-11-23

本文综述了当前用于治疗注意缺陷多动障碍(ADHD)的哌甲酯(MPH)和右哌甲酯(dexMPH)多种口服及非口服制剂,比较其暴露时间曲线特征,以协助临床个体化选择方案。文章还讨论了MPH与酒精的代谢性药物相互作用、药物基因组学预测因素以及羧酸酯酶等位基因变异对MPH代谢的影响,并提及FDA新的部分药时曲线下面积(pAUC)生物利用度指标对仿制药生物等效性评价的改进。

要点

  • 双相缓释MPH制剂的速释部分占比从15%到50%不等,不同产品暴露时间曲线各异。
  • MPH与酒精存在代谢性相互作用,可增加MPH生物利用度、增强欣快感并提高滥用风险。
  • FDA采用pAUC生物利用度指标后,两个橙皮书MR-MPH产品从AB类重编码为BX类。

核心结论

  • MPH和dexMPH制剂种类繁多,暴露时间曲线各异,需根据患者个体需求选择具体方案。

研究设计与样本

  • 本文为综述,比较了当前MPH系列药物中各成员的特征,以协助个体化选择MPH方案。

主要发现

  • 双相缓释MPH制剂的速释部分占比包括15%、20%、22%、25%、30%和37%,另有速释部分占50%的产品其脉冲式时间曲线类似每日两次速释MPH方案。
  • 2001年右旋哌甲酯(dexMPH)速释剂获批,2005年其双相缓释剂(含50%速释)获批。
  • FDA新的pAUC生物利用度指标提高了对特定仿制MR-MPH产品的区分度,导致两个橙皮书MR-MPH产品从AB类重编码为BX类。
  • MPH与酒精的代谢性药物相互作用可增加MPH生物利用度、增强欣快效应并提高滥用倾向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2000, the first biphasic modified-release (MR) formulation of methylphenidate (MPH) was approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). An immediate-release (IR) MPH pulse (22% of the dose) facilitates rapid onset of stimulant action, while the remaining MR portion of the dose provides for day-long duration of efficacy. A wide array of oral MR-MPH products has subsequently been approved that also allows for once-daily dosing, though each product is characterized by distinctive exposure time courses. This review compares each member of the current MPH armamentarium to assist in the rational selection of a specific MPH regimen for the individualized treatment of patients with ADHD. The IR portion of biphasic MPH formulations now ranges from 15%, 20%, 22%, 25%, 30%, and 37% IR-MPH, as well as a 50% IR-MPH product whose distinctly pulsatile time course closely resembles that of the pre-century "gold standard" twice-daily IR-MPH regimen. Further, transdermal, suspension, and orally disintegrating tablet products are now available to overcome any solid dosage form swallowing difficulties. Most of these formulations are racemic, though in 2001, a chiral switch drug IR-dexmethylphenidate (dexMPH) was approved, followed by biphasic MR-dexMPH (50% IR) in 2005. New U.S. Food and Drug Administration (FDA) partial area under the curve (pAUC) bioavailability metrics have improved discrimination between specific generic MR-MPH products. This has resulted in two Orange Book MR-MPH products being recoded from "AB" (i.e., meets necessary bioequivalence requirements) to "BX" (i.e., insufficient data to confirm bioequivalence). The metabolic drug interaction between MPH and alcohol, which increases MPH bioavailability, potentiates euphoric effects, and heightens abuse liability, is discussed. This review concludes with brief considerations of pharmacogenomic predictors of ADHD first-line drug selection, carboxylesterase allelic variants influencing interindividual MPH metabolism, and novel MPH formulations in the regulatory pipeline.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Patrick KS, Radke JL, Raymond JR, et al. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Pharmacotherapy. 2018. PMID: 30351459. doi:10.1002/phar.2190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。